BG64282B1 - Пироло[2,3-d]пиримидини и използван...'о им ка'о инхиби'ори на 'ирозин киназа - Google Patents

Пироло[2,3-d]пиримидини и използван...'о им ка'о инхиби'ори на 'ирозин киназа Download PDF

Info

Publication number
BG64282B1
BG64282B1 BG103785A BG10378599A BG64282B1 BG 64282 B1 BG64282 B1 BG 64282B1 BG 103785 A BG103785 A BG 103785A BG 10378599 A BG10378599 A BG 10378599A BG 64282 B1 BG64282 B1 BG 64282B1
Authority
BG
Bulgaria
Prior art keywords
phenyl
group
optionally substituted
alkyl
pyrrolo
Prior art date
Application number
BG103785A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG103785A (en
Inventor
David J. Calderwood
David N. Johnston
Paul Rafferty
Helen L. Twigger
Rainer Munschauer
Lee Arnold
Original Assignee
Abbott Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co.Kg filed Critical Abbott Gmbh & Co.Kg
Publication of BG103785A publication Critical patent/BG103785A/xx
Publication of BG64282B1 publication Critical patent/BG64282B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG103785A 1997-03-19 1999-10-07 Пироло[2,3-d]пиримидини и използван...'о им ка'о инхиби'ори на 'ирозин киназа BG64282B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4083697P 1997-03-19 1997-03-19
PCT/EP1998/001357 WO1998041525A1 (en) 1997-03-19 1998-03-09 Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
BG103785A BG103785A (en) 2000-06-30
BG64282B1 true BG64282B1 (bg) 2004-08-31

Family

ID=21913242

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103785A BG64282B1 (bg) 1997-03-19 1999-10-07 Пироло[2,3-d]пиримидини и използван...'о им ка'о инхиби'ори на 'ирозин киназа

Country Status (23)

Country Link
US (1) US6001839A (pt)
EP (1) EP0970084B1 (pt)
JP (1) JP2001516353A (pt)
KR (1) KR20000076426A (pt)
CN (1) CN1134439C (pt)
AT (1) ATE242245T1 (pt)
AU (1) AU748884B2 (pt)
BG (1) BG64282B1 (pt)
BR (1) BR9808281A (pt)
CA (1) CA2283961A1 (pt)
DE (1) DE69815317T2 (pt)
DK (1) DK0970084T3 (pt)
ES (1) ES2202827T3 (pt)
HU (1) HUP0001507A3 (pt)
ID (1) ID24653A (pt)
IL (1) IL131582A0 (pt)
NO (1) NO313962B1 (pt)
NZ (1) NZ337529A (pt)
PL (1) PL335685A1 (pt)
PT (1) PT970084E (pt)
SK (1) SK125999A3 (pt)
TR (1) TR199902301T2 (pt)
WO (1) WO1998041525A1 (pt)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
JP2002523459A (ja) * 1998-08-31 2002-07-30 メルク エンド カムパニー インコーポレーテッド 新規血管形成阻害剤
BR9913887A (pt) * 1998-09-18 2001-10-23 Basf Ag Composto, e, métodos de inibir a atividade de proteìna quinase, de tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase e de diminuir a fertilidade em um paciente
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6265403B1 (en) * 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
ATE380814T1 (de) * 1999-09-17 2007-12-15 Abbott Gmbh & Co Kg Kinaseinhibitoren als arzneimittel
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
PL354249A1 (en) 1999-09-17 2003-12-29 Abbott Gmbhabbott Gmbh Pyrazolopyrimidines as therapeutic agents
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
US7369946B2 (en) 2000-03-29 2008-05-06 Abbott Gmbh & Co. Kg Method of identifying inhibitors of Tie-2
WO2001072751A1 (en) * 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
JP2004514405A (ja) * 2000-03-29 2004-05-20 アボット　ゲーエムベーハー　ウント　カンパニー　カーゲー Ｔｉｅ−２阻害薬の特定方法
KR100403860B1 (ko) * 2000-12-27 2003-11-01 엘지전자 주식회사 차세대 이동통신 시스템의 접속시도시의 충돌감소를 위한알에이씨에이치 선택방법
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
AR035885A1 (es) * 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
AP2003002929A0 (en) * 2001-06-23 2003-12-31 Aventis Pharma Inc Pyrrolopyrimidines as protein kinase inhibitors
EP1471907B1 (en) * 2001-06-29 2008-07-16 AB Science Use of c-kit inhibitors for treating autoimmune diseases
JP2004537537A (ja) 2001-06-29 2004-12-16 アブ サイエンス 炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法
WO2003002107A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
DE60223063T2 (de) 2001-06-29 2008-07-17 Ab Science C-kit inhibitoren
JP2004537536A (ja) 2001-06-29 2004-12-16 アブ サイエンス アレルギー疾患を治療するためのチロシンキナーゼ阻害剤の使用方法
JP2004530722A (ja) * 2001-06-29 2004-10-07 アブ サイエンス 骨喪失を治療するためのチロシンキナーゼ阻害剤の使用法
JP2004537542A (ja) * 2001-06-29 2004-12-16 アブ サイエンス 炎症性腸疾患（ｉｂｄ）を治療するための、チロシンキナーゼ阻害剤の使用
GB0121033D0 (en) * 2001-08-30 2001-10-24 Novartis Ag Organic compounds
WO2003022852A2 (en) * 2001-09-11 2003-03-20 Smithkline Beecham Corporation Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
US20030225273A1 (en) * 2002-03-21 2003-12-04 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
US20030199525A1 (en) * 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
WO2004013141A1 (en) 2002-08-06 2004-02-12 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (tek) activity
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
WO2004100868A2 (en) * 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
WO2004100947A2 (en) * 2003-05-06 2004-11-25 Smithkline Beecham Corporation Novel chemical compounds
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
CA2546192C (en) * 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
EP1730148A4 (en) * 2004-02-03 2009-08-19 Abbott Lab USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS
GB0403606D0 (en) * 2004-02-18 2004-03-24 Novartis Ag Organic compounds
BRPI0511512A (pt) * 2004-05-27 2007-12-26 Pfizer Prod Inc derivados pirrolpirimidina úteis no tratamento do cáncer
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
EP1871773A1 (en) * 2005-03-17 2008-01-02 Novartis AG N-[3-(1-amino-5,6,7,8-tetrahydro-2,4,4b-triazafluoren-9-yl)-phenyl]benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
EP2532667A1 (en) * 2005-09-30 2012-12-12 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
EA015463B1 (ru) * 2005-11-17 2011-08-30 Оси Фармасьютикалз, Инк. КОНДЕНСИРОВАННОЕ БИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ - ИНГИБИТОР mTOR, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЕГО СОДЕРЖАЩАЯ, И СПОСОБ ЛЕЧЕНИЯ РАКА
CA2631664C (en) * 2005-12-08 2012-05-08 Abbott Laboratories 9-membered heterobicyclic compounds as inhibitors of protein kinases
US7659274B2 (en) * 2006-01-25 2010-02-09 Osi Pharmaceuticals, Inc. Unsaturated mTOR inhibitors
WO2007087441A2 (en) * 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
AU2007347115A1 (en) 2006-04-04 2008-10-23 The Regents Of The University Of California PI3 kinase antagonists
CL2007002617A1 (es) 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
SI2530083T1 (sl) 2006-09-22 2016-09-30 Pharmacyclics Llc Inhibitorji Bruton tirozin kinaze
EP1969934A1 (de) * 2007-03-12 2008-09-17 Bayer CropScience AG 4-Cycloalkyl-oder 4-arylsubstituierte Phenoxyphenylamidine und deren Verwendung als Fungizide
AU2008232762B2 (en) * 2007-03-28 2013-09-19 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
EP2240452B1 (en) 2008-01-04 2019-05-29 Intellikine, LLC 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives as pi3 kinase modulators, their compositions and uses
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
US8557814B2 (en) * 2008-03-19 2013-10-15 OSI Pharmaceuticals, LLC mTOR inhibitor salt forms
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CA2730106A1 (en) 2008-07-08 2010-01-14 Intellikine, Inc. Kinase inhibitors and methods of use
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
AU2009305669A1 (en) * 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US20120087915A1 (en) 2010-06-03 2012-04-12 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
NZ612909A (en) 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
CN106619647A (zh) 2011-02-23 2017-05-10 因特利凯有限责任公司 激酶抑制剂的组合及其用途
GEP20156417B (en) * 2011-04-05 2015-12-25 Pfizer Ltd Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
MX2014000518A (es) 2011-07-13 2014-05-30 Pharmacyclics Inc Inhibidores de la tirosina quinasa de bruton.
MX2014000648A (es) 2011-07-19 2014-09-25 Infinity Pharmaceuticals Inc Compuestos heterociclicos y sus usos.
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2871926A1 (en) 2012-05-03 2013-11-07 Saint Louis College Of Pharmacy Compositions and methods for increasing neurotrophic peptides
US9296753B2 (en) 2012-06-04 2016-03-29 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP3550031A1 (en) 2012-07-24 2019-10-09 Pharmacyclics, LLC Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
MA38183A1 (fr) 2012-11-15 2017-03-31 Pharmacyclics Inc Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN103333096A (zh) * 2013-06-25 2013-10-02 苏州大学 一种化学选择性制备多功能吡咯衍生物的新方法
WO2015048689A1 (en) 2013-09-30 2015-04-02 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201902074UA (en) 2013-10-04 2019-04-29 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
CA2943075C (en) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
AU2015296215A1 (en) 2014-08-01 2017-03-23 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
AU2015300798A1 (en) 2014-08-07 2017-02-02 Pharmacyclics Llc Novel formulations of a Bruton's tyrosine kinase inhibitor
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201707122QA (en) 2015-03-03 2017-09-28 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibtor
EP3334430A4 (en) * 2015-08-13 2019-02-06 San Diego State University Foundation ATROPISOMERISM FOR INCREASED KINASE HEMMER ELECTIVITY
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10561660B2 (en) 2016-06-21 2020-02-18 Nerviano Medical Sciences S.R.L. N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
RS62933B1 (sr) 2017-04-18 2022-03-31 Lilly Co Eli Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja
JP2021528444A (ja) 2018-06-21 2021-10-21 セレスティア バイオテック アーゲー アミノジアリールエーテル及びアミノジアリールエーテル塩酸塩の製造方法
MX2021002064A (es) * 2018-08-22 2021-04-28 Jiangsu Hengrui Medicine Co Metodo de preparacion del compuesto pirrolo-amino-piridazinona e intermedio del mismo.
BR112021020226A2 (pt) * 2019-04-10 2021-12-07 Cellestia Biotech Ag Inibidores de via de sinalização notch e uso dos mesmos no tratamento de cânceres
ES2974985T3 (es) * 2019-05-13 2024-07-02 Relay Therapeutics Inc Inhibidores de FGFR y métodos de uso de los mismos
CN110483523B (zh) * 2019-08-27 2022-11-22 药雅科技(上海)有限公司 一种吡唑并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途
US20220356186A1 (en) * 2019-08-29 2022-11-10 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
WO2021184154A1 (en) 2020-03-16 2021-09-23 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
TW202233625A (zh) * 2020-11-18 2022-09-01 美商傳達治療有限公司 Ｆｇｆｒ抑制劑及其製造及使用方法
WO2022109001A1 (en) 2020-11-18 2022-05-27 Deciphera Pharmaceuticals, Llc Gcn2 and perk kinase inhibitors and methods of use thereof
CA3231948A1 (en) * 2021-09-23 2023-03-30 Jingyu Hu Fgfr inhibitors and methods of use thereof
CN118369322A (zh) * 2021-12-06 2024-07-19 英矽智能科技(上海)有限公司 取代的单环或双环杂环化合物，其制法与医药上的用途
CN116903628A (zh) * 2022-04-20 2023-10-20 深圳福沃药业有限公司 Fgfr2抑制剂及使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033752A1 (en) * 1994-06-09 1995-12-14 Smithkline Beecham Corporation Endothelin receptor antagonists
CA2200210A1 (en) * 1994-09-29 1996-04-04 Novartis Ag Pyrrolo[2,3-d]pyrimidines and their use
US5639757A (en) * 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
US5665721A (en) * 1995-06-07 1997-09-09 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
CH690773A5 (de) * 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
WO1997032879A1 (de) * 1996-03-06 1997-09-12 Novartis Ag 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINE
WO1997034895A1 (de) * 1996-03-15 1997-09-25 Novartis Ag NEUE N-7 HETEROCYCLYL-PYRROLO[2,3-d]PYRIMIDINE UND IHRE VERWENDUNG

Also Published As

Publication number Publication date
JP2001516353A (ja) 2001-09-25
EP0970084A1 (en) 2000-01-12
CN1134439C (zh) 2004-01-14
DK0970084T3 (da) 2003-09-29
CA2283961A1 (en) 1998-09-24
NO994509D0 (no) 1999-09-17
BG103785A (en) 2000-06-30
EP0970084B1 (en) 2003-06-04
NZ337529A (en) 2000-10-27
ES2202827T3 (es) 2004-04-01
PT970084E (pt) 2003-10-31
CN1259950A (zh) 2000-07-12
DE69815317T2 (de) 2005-04-07
HUP0001507A2 (hu) 2000-10-28
AU6829398A (en) 1998-10-12
AU748884B2 (en) 2002-06-13
SK125999A3 (en) 2000-05-16
PL335685A1 (en) 2000-05-08
US6001839A (en) 1999-12-14
BR9808281A (pt) 2000-05-16
WO1998041525A1 (en) 1998-09-24
DE69815317D1 (de) 2003-07-10
KR20000076426A (ko) 2000-12-26
ATE242245T1 (de) 2003-06-15
NO994509L (no) 1999-09-17
HUP0001507A3 (en) 2002-01-28
NO313962B1 (no) 2003-01-06
IL131582A0 (en) 2001-01-28
TR199902301T2 (xx) 1999-12-21
ID24653A (id) 2000-07-27

Similar Documents

Publication Publication Date Title
US6001839A (en) Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors
US7863444B2 (en) 4-aminopyrrolopyrimidines as kinase inhibitors
AU752474B2 (en) 4-aminopyrrolopyrimidines as kinase inhibitors
US7829570B2 (en) Substituted 4-amino isoxazolo[5,4-d]pyrimidines as kinase inhibitors
AU753555C (en) Pyrrolopyrimidines as protein kinase inhibitors
US6921763B2 (en) Pyrazolopyrimidines as therapeutic agents
US7279473B2 (en) Pyrazolopyridazine derivatives
US20030153752A1 (en) Pyrrolopyrimidines as therapeutic agents
TW200304818A (en) Kinase inhibitors
JP2003509428A (ja) 治療薬としてのピラゾロピリミジン
US6624171B1 (en) Substituted aza-oxindole derivatives
TW200817410A (en) Triazolotriazines as kinase inhibitors
EP4157844A1 (en) 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1-(2h)-carboxamide derivatives as limk and/or rock kinases inhibitors for use in the treatment of cancer
MXPA99008171A (es) Agentes terapeuticos
CZ328399A3 (cs) Derivát pyrrolo[2,3d]pyrimidinu, způsob jeho přípravy a jeho použití
CZ2000798A3 (cs) Substituované oxindolové deriváty
MXPA01002784A (en) 4-aminopyrrolopyrimidines as kinase inhibitors